Total medical devices industry venture financing deals in Q1 2019 worth $1.43bn were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 3.05% over the previous quarter and a drop of 17.2% when compared with the last four-quarter average of $1.73bn.
The US held a 69.4% share of the global medical devices industry venture financing deal value that totalled $2.06bn in Q1 2019.
In terms of deal activity, the US recorded 148 deals during Q1 2019, marking an increase of 9% over the previous quarter and a drop of 5.1% over the last four-quarter average.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The US medical devices industry venture financing deals in Q1 2019: Top deals
The top five medical devices industry venture financing deals accounted for 27.9% of the overall value during Q1 2019.
The combined value of the top five medical devices industry venture financing deals stood at $399m, against the overall value of $1.43bn recorded for the quarter. The top announced medical devices industry venture financing deal tracked by GlobalData in Q1 2019 was Kaiser Permanente Ventures, Norwest Venture Partners XII, Orbimed Advisors, Sands Capital Ventures, Sequoia Capital Operations and UPMC Enterprises’ $100m venture financing of Health Catalyst Systems.
In second place was the $79m venture financing of Nuvaira by Advanced Technology Ventures, Endeavour Vision, LSV Capital Management, Morgenthaler Ventures, Qiming Venture Partners USA, Richard King Mellon Foundation, Split Rock Partners, USVP ManagementLlc, Versant Venture Management, Vertex Venture Holdings and Windham Venture Partners and in third place was BioStar Ventures, Michigan Accelerator Fund I and Novus Biotechnology Fund 1’s $77m venture financing of Ablative Solutions.
The $75m venture financing of Gynesonics by Abingworth Management, Advanced Technology Ventures, Bain Capital Life Sciences, Correlation Ventures, Endeavour Vision, HBM Partners, HealthCrest, Hercules Capital and Interwest Partners and Claremont Creek Ventures, Foresite Capital Management, GV Management Co, Innovatus Capital Partners, WuXi NextCODE Genomics and TPG Biotech’s venture financing of DNAnexus for $68m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.